GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pembrolizumab

Company
Vividion Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
120 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

120 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pembrolizumab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02332668

    A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 370 participants Est. completion 2028-02-02 16 sites Stand-alone
    Obstructive sleep apnea Other conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT02621021

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2029-06-16 1 site Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Recruiting NCT NCT03219450

    A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

    Not yet reported Dana-Farber Cancer Institute 15 participants Est. completion 2028-07-31 1 site Stand-alone
    Other conditions: Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT03556228

    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    Not yet reported, Not yet reported VM Oncology, LLC 242 participants Est. completion 2028-06 15 sites Stand-alone
    Other conditions: Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
    View official trial listing →
  • Recruiting NCT NCT03618550

    Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 257 participants Est. completion 2027-08 10 sites Stand-alone
    Other conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03719105

    Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

    Not yet reported New York Medical College 40 participants Est. completion 2028-12-31 6 sites Stand-alone
    Other conditions: NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03829254

    A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

    Not yet reported, Not yet reported NuCana plc 135 participants Est. completion 2026-08 9 sites Stand-alone
    Other conditions: Advanced Cancer, Lymphoma, Solid Tumor, Melanoma
    View official trial listing →
  • Recruiting NCT NCT03899155

    Pan Tumor Rollover Study

    Not yet reported Bristol-Myers Squibb 1500 participants Est. completion 2029-08-25 399 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Recruiting NCT NCT04134559

    Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

    Not yet reported Allison O'Neill, MD 18 participants Est. completion 2028-01-01 5 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma, Liver Cancer, Liver Cancer, Pediatric
    View official trial listing →
  • Recruiting NCT NCT04150640

    Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

    Not yet reported University of Wisconsin, Madison 52 participants Est. completion 2028-05 1 site Stand-alone
    Other conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT04230109

    Sacituzumab Govitecan In TNBC

    Not yet reported Massachusetts General Hospital 239 participants Est. completion 2029-10 5 sites Stand-alone
    Other conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04519151

    Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

    Not yet reported Sheba Medical Center 24 participants Est. completion 2029-11 1 site Stand-alone
    Other conditions: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoplasm of Stomach, Ovarian Diseases, Genital Neoplasms, Female, Ovarian Epithelial Tumor, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial
    View official trial listing →
  • Recruiting NCT NCT04592211

    Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

    Not yet reported, Not yet reported Yonsei University 71 participants Est. completion 2026-05-31 1 site Stand-alone
    Other conditions: Gastric Cancer Stage IV
    View official trial listing →
  • Recruiting NCT NCT04724018

    Sacituzumab Govitecan Plus EV in Metastatic UC

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 106 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
    View official trial listing →
  • Recruiting NCT NCT04754321

    Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

    Not yet reported Ohio State University Comprehensive Cancer Center 45 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT04790682

    LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

    Not yet reported Institut Curie 300 participants Est. completion 2030-06-03 3 sites Stand-alone
    Other conditions: Metastatic Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT04838652

    Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

    Not yet reported University of Cologne 29 participants Est. completion 2028-05 1 site Stand-alone
    Other conditions: Classical Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05027633

    Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

    Not yet reported M.D. Anderson Cancer Center 35 participants Est. completion 2028-03-30 1 site
    Other conditions: Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
    View official trial listing →
  • Recruiting NCT NCT05120596

    First in Human Study of T3P-Y058-739 (T3P)

    Not yet reported, Not yet reported T3 Pharmaceuticals AG 100 participants Est. completion 2027-10-15 15 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05139706

    Montreal Immune-Related Adverse Events (MIRAE) Study

    Sir Mortimer B. Davis - Jewish General Hospital 1000 participants Est. completion 2030-01 1 site
    Other conditions: Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
    View official trial listing →
  • Recruiting NCT NCT05182164

    Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

    Not yet reported Institut Bergonié 119 participants Est. completion 2027-12 10 sites Stand-alone
    Obstructive sleep apnea Other conditions: Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Undifferentiated Pleomorphic Sarcoma
    View official trial listing →
  • Recruiting NCT NCT05185739

    Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

    Not yet reported University College, London 60 participants Est. completion 2030-07 11 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05208762

    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    Not yet reported Seagen, a wholly owned subsidiary of Pfizer 714 participants Est. completion 2029-01-04 62 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05232409

    Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

    Not yet reported Valley Health System 72 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Cancer Metastatic, Metastatic Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05256745

    RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

    Not yet reported, Not yet reported Georgetown University 48 participants Est. completion 2026-12 3 sites Stand-alone
    Other conditions: Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05305131

    Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

    Not yet reported National University Hospital, Singapore 50 participants Est. completion 2026-12-28 1 site Stand-alone
    Other conditions: Nasopharyngeal Cancer
    View official trial listing →
  • Recruiting NCT NCT05338658

    Study of PAT in Patients With Solid Tumor Cancers

    Not yet reported Masonic Cancer Center, University of Minnesota 21 participants Est. completion 2027-01 1 site Stand-alone
    Other conditions: Metastasis, Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05462236

    MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

    Not yet reported AUM Biosciences Pte Ltd 120 participants Est. completion 2026-10-15 5 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT05482893

    Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    Not yet reported, Not yet reported Phanes Therapeutics 258 participants Est. completion 2028-04 11 sites Stand-alone
    Other conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
    View official trial listing →
  • Recruiting NCT NCT05563558

    Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

    Not yet reported Fundacion Oncosur 42 participants Est. completion 2026-11-01 1 site Stand-alone
    Other conditions: Prostate Cancer Metastatic
    View official trial listing →
  • Recruiting NCT NCT05579366

    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    Not yet reported, Not yet reported Genmab 884 participants Est. completion 2027-10 66 sites Stand-alone
    Other conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
    View official trial listing →
  • Recruiting NCT NCT05595447

    Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

    Not yet reported, Not yet reported Hospital Regional de Alta Especialidad del Bajio 20 participants Est. completion 2025-10-18 1 site
    Other conditions: Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
    View official trial listing →
  • Recruiting NCT NCT05651594

    Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

    Not yet reported Roswell Park Cancer Institute 40 participants Est. completion 2029-03-30 1 site Stand-alone
    Other conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT05679921

    Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

    Not yet reported Yonsei University 116 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Soft Tissue Sarcoma
    View official trial listing →
  • Recruiting NCT NCT05701527

    A Study of EBC-129 in Advanced Solid Tumours

    Not yet reported EDDC (Experimental Drug Development Centre), A*STAR Research Entities 98 participants Est. completion 2026-12-24 5 sites Stand-alone
    Other conditions: Advanced Solid Tumours
    View official trial listing →
  • Recruiting NCT NCT05725200

    Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

    Not yet reported Oslo University Hospital 40 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT05741164

    Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

    Not yet reported Emory University 37 participants Est. completion 2029-06-30 2 sites Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05745350

    First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

    Not yet reported Xiaorong Dong 45 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Small Cell Lung Cancer Extensive Stage
    View official trial listing →
  • Recruiting NCT NCT05784688

    Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported TiumBio Co., Ltd. 140 participants Est. completion 2028-12 11 sites Stand-alone
    Other conditions: Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT05785754

    DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

    Not yet reported DynamiCure Biotechnology 320 participants Est. completion 2026-12 35 sites Stand-alone
    Other conditions: Advanced or Metastatic Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT05859074

    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 56 participants Est. completion 2028-05-04 7 sites Stand-alone
    Obstructive sleep apnea Other conditions: Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05877859

    Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

    Emory University 10 participants Est. completion 2028-02-20 1 site
    Other conditions: Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
    View official trial listing →
  • Recruiting NCT NCT05899608

    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    Not yet reported Summit Therapeutics 1600 participants Est. completion 2029-12-31 260 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT05916248

    Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

    Not yet reported Ruijin Hospital 34 participants Est. completion 2026-12-30 1 site Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05920356

    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    Not yet reported Amgen 750 participants Est. completion 2032-06-29 418 sites
    Other conditions: Non-Small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Recruiting NCT NCT06001658

    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27 participants Est. completion 2028-06 1 site Stand-alone
    Other conditions: Billiary Track Cancer
    View official trial listing →
  • Recruiting NCT NCT06006013

    Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

    Not yet reported Emory University 21 participants Est. completion 2028-12-16 2 sites Stand-alone
    Other conditions: Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06031233

    Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

    Not yet reported Isala 776 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Oncology, Infusion Reaction
    View official trial listing →
  • Recruiting NCT NCT06081244

    NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

    Not yet reported Women's Cancer Study Group GmbH 348 participants Est. completion 2029-09 43 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06096844

    Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    Not yet reported National Cancer Institute (NCI) 304 participants Est. completion 2039-04-01 324 sites Stand-alone
    Other conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT06100497

    Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

    Not yet reported Beijing Tongren Hospital 100 participants Est. completion 2028-10-31 1 site Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06110793

    A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 56 participants Est. completion 2027-11 7 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06216301

    LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    Not yet reported NovoCure GmbH 734 participants Est. completion 2028-10 98 sites Stand-alone
    Other conditions: Metastatic Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06225284

    Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

    Not yet reported National Taiwan University Hospital 124 participants Est. completion 2030-12 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer, Premenopausal Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06236438

    Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported, Not yet reported AbbVie 840 participants Est. completion 2031-10 61 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06253871

    A Phase 1/1b Study of IAM1363 in HER2 Cancers

    Not yet reported Iambic Therapeutics, Inc 383 participants Est. completion 2028-12 53 sites Stand-alone
    Other conditions: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
    View official trial listing →
  • Recruiting NCT NCT06264180

    VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    Not yet reported Replimune, Inc. 400 participants Est. completion 2031-03-31 81 sites
    Other conditions: Advanced Melanoma
    View official trial listing →
  • Recruiting NCT NCT06270706

    A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    Not yet reported Pliant Therapeutics, Inc. 124 participants Est. completion 2030-06 12 sites Stand-alone
    Other conditions: Advanced or Metastatic Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT06293651

    Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

    Not yet reported, Not yet reported Dong-A ST Co., Ltd. 125 participants Est. completion 2029-10 2 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06366347

    ALPINE: Maintenance Letrozole/Abemaciclib

    Not yet reported Dana-Farber Cancer Institute 32 participants Est. completion 2029-03-01 6 sites Stand-alone
    Other conditions: Endometrial Cancer, Recurrent Endometrial Cancer, TP53
    View official trial listing →
  • Recruiting NCT NCT06377566

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 71 participants Est. completion 2027-04 8 sites Stand-alone
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06393374

    Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    Not yet reported Merck Sharp & Dohme LLC 1530 participants Est. completion 2037-12-14 310 sites Stand-alone
    Other conditions: Triple-Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06469944

    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 160 participants Est. completion 2029-09-12 50 sites Stand-alone
    Other conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
    View official trial listing →
  • Recruiting NCT NCT06513624

    ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

    Not yet reported National University Hospital, Singapore 16 participants Est. completion 2027-06-30 2 sites Stand-alone
    Other conditions: With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
    View official trial listing →
  • Recruiting NCT NCT06525220

    A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

    Not yet reported Merus B.V. 700 participants Est. completion 2030-07 205 sites Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06529809

    Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer

    Not yet reported, Not yet reported Washington University School of Medicine 50 participants Est. completion 2031-12-31 1 site
    Other conditions: Locally Advanced Cervical Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06532812

    TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

    Not yet reported, Not yet reported Essen Biotech 85 participants Est. completion 2026-12-28 1 site Stand-alone
    Other conditions: Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative
    View official trial listing →
  • Recruiting NCT NCT06543576

    External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

    Not yet reported, Not yet reported Jonsson Comprehensive Cancer Center 35 participants Est. completion 2032-01-31 4 sites Stand-alone
    Other conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
    View official trial listing →
  • Recruiting NCT NCT06551142

    A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

    Not yet reported GlaxoSmithKline 845 participants Est. completion 2029-06-08 67 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Recruiting NCT NCT06558214

    OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

    Not yet reported University of Florida 20 participants Est. completion 2029-10 1 site Stand-alone
    Other conditions: Recurrent Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT06561685

    A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    Not yet reported Eli Lilly and Company 340 participants Est. completion 2027-10 33 sites Stand-alone
    Other conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
    View official trial listing →
  • Recruiting NCT NCT06600321

    A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Not yet reported Alnylam Pharmaceuticals 158 participants Est. completion 2027-10-31 23 sites Stand-alone
    Other conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06623422

    A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Not yet reported Merck Sharp & Dohme LLC 680 participants Est. completion 2038-01-26 241 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Recruiting NCT NCT06634875

    Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

    Not yet reported Buzzard Pharmaceuticals 20 participants Est. completion 2026-12 2 sites
    Other conditions: Colorectal Cancer Metastatic
    View official trial listing →
  • Recruiting NCT NCT06648057

    Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

    CHA University 100 participants Est. completion 2026-12-31 1 site
    Other conditions: Biliary Tract Cancer, Cholangiocarcinoma
    View official trial listing →
  • Recruiting NCT NCT06692738

    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    Not yet reported AstraZeneca 1160 participants Est. completion 2030-07-01 325 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06731478

    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Not yet reported Daiichi Sankyo 726 participants Est. completion 2030-02-01 250 sites Stand-alone
    Other conditions: Gastric Cancer, Gastroesophageal Junction Cancer
    View official trial listing →
  • Recruiting NCT NCT06734533

    Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

    Hunan Cancer Hospital 80 participants Est. completion 2025-12-30 1 site
    Other conditions: HR+ Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06754644

    A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

    Not yet reported Qilu Pharmaceutical Co., Ltd. 808 participants Est. completion 2026-12 1 site
    Other conditions: NSCLC
    View official trial listing →
  • Recruiting NCT NCT06758401

    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    Not yet reported Pfizer 714 participants Est. completion 2029-03-01 372 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
    View official trial listing →
  • Recruiting NCT NCT06794645

    Pembrolizumab and Pemetrexed for Progressive Chordoma

    Not yet reported Saint John's Cancer Institute 21 participants Est. completion 2026-11-30 1 site Stand-alone
    Other conditions: Chordomas, Chordoma
    View official trial listing →
  • Recruiting NCT NCT06795412

    Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

    Not yet reported, Not yet reported Pyxis Oncology, Inc 220 participants Est. completion 2027-12-06 22 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06846268

    Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

    Not yet reported National University Hospital, Singapore 20 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Locally Advanced Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT06868433

    TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

    Not yet reported Emory University 40 participants Est. completion 2028-12-31 2 sites Stand-alone
    Other conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT06880029

    Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

    Not yet reported, Not yet reported Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. 20 participants Est. completion 2025-09-01 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer (TNBC)
    View official trial listing →
  • Recruiting NCT NCT06896422

    Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

    Not yet reported The First Affiliated Hospital of Zhengzhou University 80 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
    View official trial listing →
  • Recruiting NCT NCT06901531

    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

    Not yet reported Astellas Pharma Global Development, Inc. 500 participants Est. completion 2028-09-30 250 sites Stand-alone
    Other conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT06904573

    Probiotics in Advanced Urothelial Carcinoma

    Not yet reported Sun Yat-sen University 222 participants Est. completion 2028-01-01 3 sites Stand-alone
    Other conditions: Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
    View official trial listing →
  • Recruiting NCT NCT06912087

    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

    Not yet reported University of Chicago 36 participants Est. completion 2027-06-05 1 site Stand-alone
    Other conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06999980

    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

    Not yet reported Melanoma Institute Australia 494 participants Est. completion 2038-01 1 site
    Obstructive sleep apnea Other conditions: Cutaneous Melanoma
    View official trial listing →
  • Recruiting NCT NCT07000253

    Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 290 participants Est. completion 2034-01 5 sites Stand-alone
    Other conditions: Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Esophageal Carcinoma, Gastric (Cardia, Body) Cancer
    View official trial listing →
  • Recruiting NCT NCT07014202

    Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 224 participants Est. completion 2027-09-01 1 site Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07021989

    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

    Not yet reported Michael Spinner, MD 38 participants Est. completion 2034-03-31 6 sites Stand-alone
    Other conditions: Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07054567

    A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

    Not yet reported Sichuan Baili Pharmaceutical Co., Ltd. 96 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Cervical Cancer, Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT07061964

    Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

    Not yet reported National Cancer Institute (NCI) 111 participants Est. completion 2027-07-31 165 sites Stand-alone
    Other conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT07066917

    Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer

    Hellenic Cooperative Oncology Group 150 participants Est. completion 2029-10 5 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07094113

    AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    Not yet reported Amgen 434 participants Est. completion 2031-04-20 39 sites Stand-alone
    Other conditions: KRAS Altered Advanced or Metastatic Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07123415

    A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

    Not yet reported Aptabio Therapeutics, Inc. 110 participants Est. completion 2028-12 3 sites Stand-alone
    Other conditions: Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
    View official trial listing →
  • Recruiting NCT NCT07158918

    ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

    Not yet reported, Not yet reported ABL Bio, Inc. 65 participants Est. completion 2027-12-02 6 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07174453

    Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

    Not yet reported University of Kansas Medical Center 192 participants Est. completion 2029-10-01 1 site Stand-alone
    Other conditions: Solid Tumor Malignancies
    View official trial listing →
  • Recruiting NCT NCT07182591

    A Study of DS5361b in Participants With Advanced Solid Tumors

    Not yet reported Daiichi Sankyo 192 participants Est. completion 2030-12-03 7 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT07197827

    A Study of YL242 in Subjects With Advanced Solid Tumors

    Not yet reported, Not yet reported MediLink Therapeutics (Suzhou) Co., Ltd. 424 participants Est. completion 2028-11 15 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT07231458

    A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

    Not yet reported Abalos Therapeutics GmbH 27 participants Est. completion 2026-10-30 5 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07232602

    KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 55 participants Est. completion 2031-07-08 16 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Recruiting NCT NCT07262619

    EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

    Not yet reported, Not yet reported Eikon Therapeutics 160 participants Est. completion 2029-03 10 sites Stand-alone
    Other conditions: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07276399

    A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

    Not yet reported Janssen Research & Development, LLC 500 participants Est. completion 2029-06-18 201 sites Stand-alone
    Other conditions: Squamous Cell Carcinoma of Head and Neck
    View official trial listing →
  • Recruiting NCT NCT07282262

    An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

    Not yet reported Peking Union Medical College Hospital 300 participants Est. completion 2026-10-01 1 site Stand-alone
    Other conditions: Biliary Tract Cancer
    View official trial listing →
  • Recruiting NCT NCT07283822

    Amping up With PemJAK

    Not yet reported Seda S. Tolu 53 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent, Gray Zone Lymphoma, Peripheral T-cell Lymphoma, Cutaneous T-Cell Lymphomas, Primary Mediastinal B Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07290894

    Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

    Not yet reported National Cancer Institute, Naples 80 participants Est. completion 2031-10 1 site Stand-alone
    Other conditions: Vulva Cancer
    View official trial listing →
  • Recruiting NCT NCT07362459

    A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

    Not yet reported Sinocelltech Ltd. 246 participants Est. completion 2029-09 1 site
    Other conditions: Non-Small Cell Lung Carcinoma (NSCLC)
    View official trial listing →
  • Recruiting NCT NCT07394062

    Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

    Gazi University 400 participants Est. completion 2028-02 2 sites
    Other conditions: Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07405151

    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 60 participants Est. completion 2028-06-12 31 sites
    Other conditions: Oesophageal Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07415031

    A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

    Not yet reported Mirati Therapeutics Inc. 170 participants Est. completion 2028-02-16 100 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07448831

    A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

    Not yet reported Universitair Ziekenhuis Brussel 49 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Melanoma (Skin Cancer)
    View official trial listing →
  • Recruiting NCT NCT07486817

    Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

    Not yet reported Boehringer Ingelheim 60 participants Est. completion 2029-08-25 17 sites Stand-alone
    Other conditions: Lung Cancer, Non-squamous, Non-small Cell
    View official trial listing →
  • Recruiting NCT NCT07579195

    Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

    Not yet reported, Not yet reported University of Washington 12 participants Est. completion 2030-02-01 1 site Stand-alone
    Other conditions: Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT07652242

    Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    Not yet reported Immunomic Therapeutics, Inc. 60 participants Est. completion 2028-08 2 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer (TNBC)
    View official trial listing →
  • Recruiting NCT NCT07720284

    An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

    Not yet reported AstraZeneca 915 participants Est. completion 2032-11-23 160 sites
    Other conditions: High-risk Muscle Invasive Urothelial Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07811193

    A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

    Not yet reported Vividion Therapeutics, Inc. 140 participants Est. completion 2030-12-31 122 sites Stand-alone
    Other conditions: Colorectal Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT07815665

    A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

    Not yet reported, Not yet reported Summit Therapeutics 800 participants Est. completion 2030-12-31 7 sites
    Other conditions: Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
    View official trial listing →
  • Completed NCT NCT01876511

    Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 113 participants Est. completion 2019-08 7 sites
    Other conditions: MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
    View official trial listing →
  • Completed NCT NCT02073123

    Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

    Not yet reported, Not yet reported NewLink Genetics Corporation 131 participants Est. completion 2019-07-03 6 sites Stand-alone
    Other conditions: Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
    View official trial listing →
  • Completed NCT NCT02142738

    Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

    Not yet reported Merck Sharp & Dohme LLC 305 participants Est. completion 2021-05-27 Stand-alone
    Other conditions: Non-Small Cell Lung Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT02287428

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

    Not yet reported Dana-Farber Cancer Institute 56 participants Est. completion 2028-02 2 sites Stand-alone
    Other conditions: Glioblastoma
    View official trial listing →
  • Completed NCT NCT02289209

    Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

    Not yet reported Dan Zandberg 48 participants Est. completion 2024-08-31 4 sites Stand-alone
    Other conditions: Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
    View official trial listing →
  • Completed NCT NCT02296684

    Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

    Not yet reported Washington University School of Medicine 67 participants Est. completion 2025-07-21 3 sites
    Other conditions: Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
    View official trial listing →
  • Completed NCT NCT02337491

    Pembrolizumab +/- Bevacizumab for Recurrent GBM

    Not yet reported Dana-Farber Cancer Institute 80 participants Est. completion 2020-09-14 8 sites Stand-alone
    Other conditions: Glioblastoma
    View official trial listing →
  • Completed NCT NCT02343952

    Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

    Not yet reported Nasser Hanna, M.D. 93 participants Est. completion 2021-01-01 15 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Terminated NCT NCT02382406

    Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

    Not yet reported, Not yet reported Nisha Mohindra, MD 46 participants Est. completion 2022-04-14 5 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02399371

    Pembrolizumab in Treating Patients With Malignant Mesothelioma

    Not yet reported University of Chicago 65 participants Est. completion 2026-03-20 1 site Stand-alone
    Other conditions: Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Sarcomatoid Mesothelioma
    View official trial listing →
  • Completed NCT NCT02402920

    Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

    Not yet reported M.D. Anderson Cancer Center 83 participants Est. completion 2026-02-09 1 site Stand-alone
    Other conditions: Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT02411656

    Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

    Not yet reported M.D. Anderson Cancer Center 71 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT02439450

    A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Heat Biologics 121 participants Est. completion 2022-11-04 16 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02444741

    Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 124 participants Est. completion 2026-02-17 1 site Stand-alone
    Other conditions: Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
    View official trial listing →
  • Active, not recruiting NCT NCT02446457

    Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 53 participants Est. completion 2026-04-30 1 site Stand-alone
    Other conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02454179

    Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

    Not yet reported Acerta Pharma BV 78 participants Est. completion 2018-07 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma of the Head and Neck
    View official trial listing →
  • Completed NCT NCT02467361

    A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

    Not yet reported Sumitomo Pharma America, Inc. 104 participants Est. completion 2021-01-29 8 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02475213

    Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

    Not yet reported MacroGenics 146 participants Est. completion 2021-08-18 20 sites Stand-alone
    Other conditions: Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT02493361

    Trial of pIL-12/MK-3475 in Metastatic Melanoma

    Not yet reported University of California, San Francisco 24 participants Est. completion 2020-03-02 2 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT02500576

    Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2022-10-12 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
    View official trial listing →
  • Terminated NCT NCT02501473

    Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

    Not yet reported, Not yet reported Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 52 participants Est. completion 2019-08-01 Stand-alone
    Other conditions: Follicular Low Grade Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02512172

    A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27 participants Est. completion 2021-11-20 1 site
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Terminated NCT NCT02521870

    A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not yet reported, Not yet reported Dynavax Technologies Corporation 241 participants Est. completion 2020-04 47 sites Stand-alone
    Other conditions: Metastatic Melanoma, Head Neck Cancer
    View official trial listing →
  • Completed NCT NCT02541565

    Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

    Not yet reported University of Washington 30 participants Est. completion 2018-12-18 1 site Stand-alone
    Other conditions: Composite Lymphoma, Grade 3b Follicular Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage I Follicular Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage II Follicular Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage III Follicular Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Stage IV Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02555657

    Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

    Not yet reported Merck Sharp & Dohme LLC 622 participants Est. completion 2020-11-10 Stand-alone
    Other conditions: Metastatic Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02564380

    Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)

    Not yet reported AIO-Studien-gGmbH 41 participants Est. completion 2020-11-23 1 site Stand-alone
    Other conditions: Metastatic Squamous Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02575404

    GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

    Not yet reported Providence Health & Services 36 participants Est. completion 2022-10-10 1 site Stand-alone
    Other conditions: Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
    View official trial listing →
  • Completed NCT NCT02576990

    Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

    Not yet reported Merck Sharp & Dohme LLC 80 participants Est. completion 2020-10-23 Stand-alone
    Other conditions: Mediastinal Large B-cell Lymphoma, Richter Syndrome
    View official trial listing →
  • Completed NCT NCT02591615

    Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

    Not yet reported Alliance Foundation Trials, LLC. 91 participants Est. completion 2020-07-04 11 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02595866

    Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

    Not yet reported National Cancer Institute (NCI) 58 participants Est. completion 2024-03-25 12 sites Stand-alone
    Other conditions: AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
    View official trial listing →
  • Completed NCT NCT02621398

    Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

    Not yet reported Rutgers, The State University of New Jersey 23 participants Est. completion 2024-02-29 3 sites Stand-alone
    Other conditions: Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT02625961

    Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

    Not yet reported Merck Sharp & Dohme LLC 296 participants Est. completion 2025-11-05 Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Withdrawn NCT NCT02661100

    A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

    Not yet reported, Not yet reported Case Comprehensive Cancer Center Est. completion 2018-07 Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer, Mesothelioma, Malignant Melanoma
    View official trial listing →
  • Completed NCT NCT02680184

    Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

    Not yet reported Regeneron Pharmaceuticals 199 participants Est. completion 2022-12-06 13 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Terminated NCT NCT02684617

    Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

    Not yet reported Merck Sharp & Dohme LLC 75 participants Est. completion 2020-04-06 Stand-alone
    Other conditions: rrCLL, rrMM, rrDLBCL
    View official trial listing →
  • Completed NCT NCT02688608

    Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

    Not yet reported Saad A Khan 6 participants Est. completion 2021-10 1 site Stand-alone
    Other conditions: Anaplastic Thyroid Cancer
    View official trial listing →
  • Completed NCT NCT02690948

    Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

    Not yet reported, Not yet reported Anne Chang 16 participants Est. completion 2018-08-29 1 site Stand-alone
    Other conditions: Skin Basal Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT02691026

    A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery

    Not yet reported Oslo University Hospital 8 participants Est. completion 2020-12 1 site Stand-alone
    Other conditions: Malignant Peripheral Nerve Sheath Tumour (MPNST)
    View official trial listing →
  • Terminated NCT NCT02706353

    APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 34 participants Est. completion 2025-03-10 1 site Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT02713373

    Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

    Not yet reported, Not yet reported Roswell Park Cancer Institute 45 participants Est. completion 2021-07-20 2 sites Stand-alone
    Other conditions: Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT02733159

    Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

    Not yet reported University of Birmingham 62 participants Est. completion 2024-02-05 10 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Completed NCT NCT02733250

    Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Centre hospitalier de l'Université de Montréal (CHUM) 10 participants Est. completion 2019-12-13 2 sites
    Other conditions: Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02734290

    Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

    Not yet reported, Not yet reported Providence Health & Services 29 participants Est. completion 2026-12 2 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02767934

    Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

    Not yet reported University of Washington 12 participants Est. completion 2019-12-17 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT02794571

    Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

    Not yet reported Genentech, Inc. 518 participants Est. completion 2024-11-13 28 sites Stand-alone
    Other conditions: Advanced/Metastatic Tumors
    View official trial listing →
  • Completed NCT NCT02808143

    Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

    Not yet reported Northwestern University 9 participants Est. completion 2022-08-05 1 site Stand-alone
    Other conditions: Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
    View official trial listing →
  • Completed NCT NCT02845297

    Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67 participants Est. completion 2022-12 3 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT02851004

    Special Combination of BBI608 and Pembrolizumab

    Not yet reported, Not yet reported Takayuki Yoshino 55 participants Est. completion 2021-08-23 1 site Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT02872259

    BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

    Not yet reported, Not yet reported Haukeland University Hospital 74 participants Est. completion 2024-05-23 5 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT02875132

    Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

    Not yet reported Chinese University of Hong Kong 9 participants Est. completion 2022-02-28 1 site Stand-alone
    Other conditions: Acral Lentiginous Melanoma
    View official trial listing →
  • Completed NCT NCT02901899

    Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not yet reported Northwestern University 45 participants Est. completion 2023-03-31 3 sites Stand-alone
    Other conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
    View official trial listing →
  • Completed NCT NCT02902042

    Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

    Not yet reported, Not yet reported Prof. Dr. med. Dirk Schadendorf 16 participants Est. completion 2020-11-30 11 sites Stand-alone
    Other conditions: Malignant Melanoma
    View official trial listing →
  • Completed NCT NCT02904226

    JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

    Not yet reported, Not yet reported Jounce Therapeutics, Inc. 242 participants Est. completion 2020-07-01 16 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02909348

    Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab

    Royal Free Hospital NHS Foundation Trust 25 participants Est. completion 2019-10 2 sites
    Other conditions: Neoplasms, Melanoma
    View official trial listing →
  • Completed NCT NCT02909452

    Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

    Not yet reported Syndax Pharmaceuticals 30 participants Est. completion 2021-02-09 1 site
    Other conditions: Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors
    View official trial listing →
  • Completed NCT NCT02939651

    A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

    Not yet reported Fox Chase Cancer Center 21 participants Est. completion 2020-03 2 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT02940496

    Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

    Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2023-08-09 1 site Stand-alone
    Other conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7
    View official trial listing →
  • Status unknown NCT NCT02949219

    Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

    Not yet reported Academic and Community Cancer Research United 41 participants Est. completion 2024-12-31 8 sites Stand-alone
    Other conditions: Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma
    View official trial listing →
  • Completed NCT NCT02959463

    Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

    Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2026-04-27 1 site Stand-alone
    Other conditions: Pleural Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT02960230

    H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

    Not yet reported, Not yet reported Sabine Mueller, MD, PhD 50 participants Est. completion 2023-12-31 15 sites
    Other conditions: Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
    View official trial listing →
  • Completed NCT NCT02981303

    Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

    Not yet reported HiberCell, Inc. 64 participants Est. completion 2020-12-31 10 sites Stand-alone
    Other conditions: Advanced Melanoma, Triple-Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02990845

    Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported National Taiwan University Hospital 16 participants Est. completion 2022-08-16 1 site Stand-alone
    Other conditions: Premenopausal Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03009058

    Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

    Not yet reported, Not yet reported Immodulon Therapeutics Ltd 2 participants Est. completion 2017-08-30 4 sites Stand-alone
    Other conditions: Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT03010176

    Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

    Not yet reported Merck Sharp & Dohme LLC 156 participants Est. completion 2022-04-21 19 sites Stand-alone
    Other conditions: Solid Tumors, Lymphoma
    View official trial listing →
  • Completed NCT NCT03018080

    Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

    Not yet reported Wake Forest University Health Sciences 40 participants Est. completion 2022-08-05 1 site Stand-alone
    Other conditions: Breast - Female, Male Breast Cancer
    View official trial listing →
  • Completed NCT NCT03021460

    Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

    Not yet reported Mayo Clinic 20 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
    View official trial listing →
  • Completed NCT NCT03025880

    Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

    Not yet reported Spanish Breast Cancer Research Group 36 participants Est. completion 2021-07-22 9 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT03029598

    Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not yet reported, Not yet reported University of Washington 29 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
    View official trial listing →
  • Completed NCT NCT03056599

    Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

    Not yet reported Presage Biosciences 23 participants Est. completion 2021-09-22 3 sites
    Other conditions: Soft Tissue Sarcoma Adult
    View official trial listing →
  • Completed NCT NCT03065400

    PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

    Not yet reported John Mascarenhas 10 participants Est. completion 2020-05-28 3 sites Stand-alone
    Other conditions: Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
    View official trial listing →
  • Completed NCT NCT03070392

    Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

    Not yet reported Immunocore Ltd 378 participants Est. completion 2025-09-17 57 sites
    Other conditions: Uveal Melanoma
    View official trial listing →
  • Completed NCT NCT03095352

    Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

    Not yet reported Laura Huppert, MD, BA 76 participants Est. completion 2024-11-30 7 sites Stand-alone
    Other conditions: Breast Cancer, Chest Wall Disease
    View official trial listing →
  • Completed NCT NCT03095781

    Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

    Not yet reported Emory University 47 participants Est. completion 2021-06-10 3 sites Stand-alone
    Other conditions: Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
    View official trial listing →
  • Terminated NCT NCT03115801

    A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

    Not yet reported Weill Medical College of Cornell University 6 participants Est. completion 2020-10-13 1 site
    Other conditions: Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT03126591

    A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

    Not yet reported Eli Lilly and Company 41 participants Est. completion 2023-02-21 6 sites Stand-alone
    Other conditions: Soft Tissue Sarcoma
    View official trial listing →
  • Active, not recruiting NCT NCT03126630

    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 49 participants Est. completion 2027-02-25 33 sites Stand-alone
    Other conditions: Pleural Malignant Mesothelioma
    View official trial listing →
  • Terminated NCT NCT03144466

    A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer

    Not yet reported Royal Marsden NHS Foundation Trust 1 participants Est. completion 2019-01-31 1 site Stand-alone
    Other conditions: Cervix Cancer
    View official trial listing →
  • Completed NCT NCT03149822

    Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

    Not yet reported, Not yet reported University of Colorado, Denver 45 participants Est. completion 2024-02-16 5 sites Stand-alone
    Other conditions: Metastatic Renal Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT03167151

    Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

    Not yet reported, Not yet reported University of Oxford 6 participants Est. completion 2019-06-26 3 sites Stand-alone
    Other conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
    View official trial listing →
  • Withdrawn NCT NCT03182894

    Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

    Not yet reported, Not yet reported James J Lee Est. completion 2020-07-30 1 site Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Withdrawn NCT NCT03189186

    Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

    Not yet reported University of California, Irvine Est. completion 2018-10-17 1 site Stand-alone
    Other conditions: Renal Cell Carcinoma, Metastatic Kidney Cancer
    View official trial listing →
  • Completed NCT NCT03190811

    Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

    Not yet reported, Not yet reported Capital Medical University 100 participants Est. completion 2023-06 1 site Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT03197389

    Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

    Not yet reported Universitaire Ziekenhuizen KU Leuven 54 participants Est. completion 2020-03-31 1 site
    Other conditions: Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT03197506

    Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

    Not yet reported Mayo Clinic 52 participants Est. completion 2028-06-06 3 sites Stand-alone
    Obstructive sleep apnea Other conditions: Glioblastoma, Supratentorial Glioblastoma
    View official trial listing →
  • Completed NCT NCT03211416

    Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

    Not yet reported, Not yet reported Roswell Park Cancer Institute 37 participants Est. completion 2025-08-15 2 sites Stand-alone
    Other conditions: Advanced Adult Hepatocellular Carcinoma, Child-Pugh Class A, Stage III Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IV Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT03217071

    Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

    Not yet reported Sue Yom 12 participants Est. completion 2022-03-31 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT03221634

    Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

    Not yet reported Merck Sharp & Dohme LLC Est. completion 2021-06-10 23 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03228667

    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

    Not yet reported ImmunityBio, Inc. 40 participants Est. completion 2030-12-31 35 sites Stand-alone
    Obstructive sleep apnea Other conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Mismatch Repair Deficiency, Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT03240016

    Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

    Not yet reported University of Michigan Rogel Cancer Center 36 participants Est. completion 2023-06-23 1 site Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Terminated NCT NCT03249792

    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

    Not yet reported Merck Sharp & Dohme LLC 140 participants Est. completion 2023-02-22 8 sites Stand-alone
    Other conditions: Solid Tumor, Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03277638

    Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

    Not yet reported, Not yet reported Case Comprehensive Cancer Center 32 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Glioblastoma, Adult
    View official trial listing →
  • Active, not recruiting NCT NCT03278782

    Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 39 participants Est. completion 2027-07-31 1 site Stand-alone
    Other conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03284424

    Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

    Not yet reported Merck Sharp & Dohme LLC 159 participants Est. completion 2023-09-13 59 sites Stand-alone
    Other conditions: Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT03291054

    Epacadostat and Pembrolizumab in Patients With GIST

    Not yet reported Columbia University 1 participants Est. completion 2020-08-19 2 sites Stand-alone
    Other conditions: Gastrointestinal Stromal Tumors
    View official trial listing →
  • Completed NCT NCT03299088

    Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

    Not yet reported Jonathan Riess 15 participants Est. completion 2024-06-25 1 site Stand-alone
    Other conditions: KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT03304639

    Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

    Not yet reported National Cancer Institute (NCI) 9 participants Est. completion 2026-02-19 254 sites Stand-alone
    Other conditions: Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
    View official trial listing →
  • Terminated NCT NCT03307759

    Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

    Not yet reported Peter MacCallum Cancer Centre, Australia 13 participants Est. completion 2022-01-31 1 site
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03308942

    Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

    Not yet reported Tesaro, Inc. 53 participants Est. completion 2021-08-31 16 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Terminated NCT NCT03311334

    A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported Sumitomo Pharma America, Inc. 47 participants Est. completion 2022-11-29 19 sites Stand-alone
    Other conditions: Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03313206

    Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 60 participants Est. completion 2029-01 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Terminated NCT NCT03316872

    Study of Pembrolizumab and Radiotherapy in Liver Cancer

    Not yet reported University Health Network, Toronto 18 participants Est. completion 2024-02-15 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT03322566

    A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

    Not yet reported Incyte Corporation 233 participants Est. completion 2020-10-16 94 sites Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Terminated NCT NCT03325166

    Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

    Not yet reported OHSU Knight Cancer Institute 2 participants Est. completion 2021-03-01 1 site Stand-alone
    Other conditions: Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
    View official trial listing →
  • Withdrawn NCT NCT03325465

    Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

    Not yet reported University of Chicago Est. completion 2018-11-07 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma of the Head and Neck
    View official trial listing →
  • Completed NCT NCT03332498

    Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 40 participants Est. completion 2021-09-09 1 site Stand-alone
    Other conditions: Colon Cancer, Colorectal Cancer, Colorectal Carcinoma, Colon Disease
    View official trial listing →
  • Completed NCT NCT03342937

    KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

    Not yet reported Duke University 36 participants Est. completion 2023-02-06 7 sites Stand-alone
    Other conditions: Gastric Cancer, Esophagus Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT03345134

    Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

    Not yet reported Shaheen Alanee 20 participants Est. completion 2021-01-01 1 site
    Other conditions: High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
    View official trial listing →
  • Completed NCT NCT03348891

    TNF in Melanoma Patients Treated With Immunotherapy

    Not yet reported Institut Claudius Regaud 60 participants Est. completion 2021-11-22 3 sites
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT03360630

    Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

    Not yet reported, Not yet reported Capital Medical University 60 participants Est. completion 2023-06-01 1 site Stand-alone
    Other conditions: Lung Cancer, Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT03361852

    Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

    Not yet reported Dana-Farber Cancer Institute 20 participants Est. completion 2033-12-26 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03362060

    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

    Not yet reported Massachusetts General Hospital 20 participants Est. completion 2027-12-30 3 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03364049

    Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

    Not yet reported Merck Sharp & Dohme LLC 33 participants Est. completion 2020-10-19 6 sites Stand-alone
    Other conditions: Solid Neoplasms
    View official trial listing →
  • Completed NCT NCT03374254

    Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

    Not yet reported Merck Sharp & Dohme LLC 116 participants Est. completion 2023-07-18 14 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT03374488

    Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

    Not yet reported Incyte Corporation 84 participants Est. completion 2020-07-23 135 sites Stand-alone
    Other conditions: UC (Urothelial Cancer)
    View official trial listing →
  • Completed NCT NCT03380871

    A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

    Not yet reported BioNTech US Inc. 38 participants Est. completion 2021-02-05 5 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung
    View official trial listing →
  • Completed NCT NCT03382600

    Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

    Not yet reported Merck Sharp & Dohme LLC 100 participants Est. completion 2021-05-30 25 sites Stand-alone
    Other conditions: Gastric Cancer
    View official trial listing →
  • Completed NCT NCT03391973

    Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

    Not yet reported AHS Cancer Control Alberta 33 participants Est. completion 2026-02-12 3 sites Stand-alone
    Other conditions: Carcinoma of Unknown Primary
    View official trial listing →
  • Terminated NCT NCT03396471

    Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

    Not yet reported Hoosier Cancer Research Network 14 participants Est. completion 2023-03-02 2 sites Stand-alone
    Other conditions: Carcinoma, Unspecified Site
    View official trial listing →
  • Withdrawn NCT NCT03402880

    ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

    Not yet reported City of Hope Medical Center Est. completion 2018-10-03 3 sites Stand-alone
    Other conditions: Extensive Stage Small Cell Lung Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03405792

    Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

    Not yet reported University of Florida 40 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Glioblastoma, Glioblastoma, WHO Grade IV
    View official trial listing →
  • Terminated NCT NCT03407976

    Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

    Not yet reported University of Utah 5 participants Est. completion 2020-07-02 1 site Stand-alone
    Other conditions: Advanced Malignancies, Urothelial Carcinoma, MSI-H or dMMR Solid Tumors, Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03409016

    Biomarkers of Immune-Related Toxicity

    University of Colorado, Denver 69 participants Est. completion 2026-10-17 1 site
    Other conditions: Cancer, Metastatic Cancer
    View official trial listing →
  • Terminated NCT NCT03416335

    A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

    Not yet reported, Not yet reported Sumitomo Pharma America, Inc. 36 participants Est. completion 2022-12-20 5 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Terminated NCT NCT03417882

    GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

    Not yet reported BrightPath Biotherapeutics 20 participants Est. completion 2022-12-05 11 sites Stand-alone
    Other conditions: Metastatic NSCLC
    View official trial listing →
  • Terminated NCT NCT03425006

    Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

    Not yet reported University of Pennsylvania 23 participants Est. completion 2021-10-11 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03428802

    Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

    Not yet reported Rutgers, The State University of New Jersey 21 participants Est. completion 2027-09-21 2 sites Stand-alone
    Other conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
    View official trial listing →
  • Withdrawn NCT NCT03432676

    Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

    Not yet reported M.D. Anderson Cancer Center Est. completion 2021-04-30 Stand-alone
    Other conditions: ATM Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Homologous Recombination Deficiency, Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT03447678

    Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 65 participants Est. completion 2022-05-31 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Status unknown NCT NCT03469804

    Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma

    Not yet reported Assistance Publique - Hôpitaux de Paris 17 participants Est. completion 2020-09-20 1 site Stand-alone
    Other conditions: Kaposi Sarcoma, Progression, Disease
    View official trial listing →
  • Completed NCT NCT03473925

    Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

    Not yet reported Merck Sharp & Dohme LLC 107 participants Est. completion 2021-05-19 14 sites Stand-alone
    Obstructive sleep apnea Other conditions: Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer
    View official trial listing →
  • Completed NCT NCT03475004

    Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

    Not yet reported University of Colorado, Denver 53 participants Est. completion 2024-02-12 1 site Stand-alone
    Other conditions: Colorectal Cancer, Metastatic Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03488667

    Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

    Not yet reported University of Kansas Medical Center 40 participants Est. completion 2025-04-30 1 site Stand-alone
    Other conditions: Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT03506997

    Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

    Not yet reported Institute of Cancer Research, United Kingdom 100 participants Est. completion 2025-09-01 1 site Stand-alone
    Other conditions: Castration-resistant Prostate Cancer
    View official trial listing →
  • Completed NCT NCT03517449

    Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

    Not yet reported Eisai Inc. 827 participants Est. completion 2025-02-26 169 sites Stand-alone
    Other conditions: Endometrial Neoplasms
    View official trial listing →
  • Status unknown NCT NCT03539328

    Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 138 participants Est. completion 2022-04 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Terminated NCT NCT03544099

    Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA

    Not yet reported National Health Research Institutes, Taiwan 2 participants Est. completion 2021-12-31 8 sites Stand-alone
    Other conditions: Nasopharyngeal Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03546426

    Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 18 participants Est. completion 2028-09 1 site Stand-alone
    Other conditions: Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
    View official trial listing →
  • Active, not recruiting NCT NCT03582475

    Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

    Not yet reported Jonsson Comprehensive Cancer Center 15 participants Est. completion 2026-12-01 1 site Stand-alone
    Other conditions: Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT03592407

    Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

    Not yet reported City of Hope Medical Center Est. completion 2020-04 3 sites Stand-alone
    Other conditions: Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT03596281

    Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 47 participants Est. completion 2023-04-11 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Terminated NCT NCT03631199

    Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

    Not yet reported Novartis Pharmaceuticals 673 participants Est. completion 2026-01-26 152 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03633110

    Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

    Not yet reported, Not yet reported Genocea Biosciences, Inc. 24 participants Est. completion 2022-02-28 11 sites Stand-alone
    Other conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT03634332

    Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

    Not yet reported Pancreatic Cancer Research Team 35 participants Est. completion 2021-01 5 sites Stand-alone
    Other conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
    View official trial listing →
  • Terminated NCT NCT03637803

    Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

    Not yet reported, Not yet reported 4D pharma plc 63 participants Est. completion 2023-05-08 5 sites Stand-alone
    Other conditions: Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
    View official trial listing →
  • Terminated NCT NCT03644550

    Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

    Not yet reported National Cancer Institute (NCI) 18 participants Est. completion 2020-11-02 1 site Stand-alone
    Other conditions: Mesothelioma
    View official trial listing →
  • Completed NCT NCT03665545

    Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

    Not yet reported, Not yet reported University Hospital, Geneva 18 participants Est. completion 2024-04-24 1 site Stand-alone
    Other conditions: Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
    View official trial listing →
  • Terminated NCT NCT03694834

    Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

    Not yet reported UNC Lineberger Comprehensive Cancer Center 3 participants Est. completion 2023-10-23 1 site Stand-alone
    Other conditions: Endometrial Cancer, Uterine Cancer
    View official trial listing →
  • Completed NCT NCT03713593

    Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

    Not yet reported Merck Sharp & Dohme LLC 794 participants Est. completion 2024-09-24 172 sites Stand-alone
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Completed NCT NCT03715205

    Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

    Not yet reported Merck Sharp & Dohme LLC 150 participants Est. completion 2024-08-21 8 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT03725059

    Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

    Not yet reported Merck Sharp & Dohme LLC 1240 participants Est. completion 2031-01-24 244 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03734809

    NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer

    Not yet reported Chinese University of Hong Kong 43 participants Est. completion 2027-12-31 2 sites Stand-alone
    Other conditions: NPC
    View official trial listing →
  • Completed NCT NCT03752333

    Trial of Pembrolizumab in Cancer of Unknown Primary

    Not yet reported Imperial College London 35 participants Est. completion 2025-03-31 3 sites Stand-alone
    Other conditions: Cancer of Unknown Primary Site
    View official trial listing →
  • Active, not recruiting NCT NCT03765918

    Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

    Not yet reported Merck Sharp & Dohme LLC 714 participants Est. completion 2026-11-17 192 sites Stand-alone
    Other conditions: Head and Neck Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT03768063

    A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

    Not yet reported Hoffmann-La Roche 1000 participants Est. completion 2028-07-05 80 sites
    Other conditions: Cancer
    View official trial listing →
  • Terminated NCT NCT03776864

    Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

    Not yet reported University of Washington 6 participants Est. completion 2021-09-14 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT03809624

    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

    Not yet reported Inhibrx Biosciences, Inc 160 participants Est. completion 2024-10-03 23 sites Stand-alone
    Other conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03813836

    Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

    Not yet reported University College, London 63 participants Est. completion 2026-01-31 12 sites Stand-alone
    Other conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT03829319

    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

    Not yet reported Merck Sharp & Dohme LLC 761 participants Est. completion 2024-08-30 158 sites Stand-alone
    Other conditions: Nonsquamous Non-small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT03832673

    Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Est. completion 2019-05-22 1 site Stand-alone
    Other conditions: Muscle-invasive Bladder Cancer
    View official trial listing →
  • Completed NCT NCT03834493

    Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

    Not yet reported Merck Sharp & Dohme LLC 1244 participants Est. completion 2026-06-08 259 sites Stand-alone
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Completed NCT NCT03834506

    Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

    Not yet reported Merck Sharp & Dohme LLC 1030 participants Est. completion 2023-07-18 215 sites Stand-alone
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Completed NCT NCT03834519

    Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

    Not yet reported Merck Sharp & Dohme LLC 793 participants Est. completion 2024-01-27 193 sites Stand-alone
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Completed NCT NCT03846310

    A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

    Not yet reported Arcus Biosciences, Inc. 77 participants Est. completion 2024-11-18 22 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
    View official trial listing →
  • Completed NCT NCT03847519

    Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Advaxis, Inc. 24 participants Est. completion 2022-02-22 9 sites Stand-alone
    Other conditions: Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT03848845

    Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported GlaxoSmithKline 41 participants Est. completion 2023-06-14 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03858582

    neoadjuvant_thymic Epithelial Tumor

    Not yet reported Samsung Medical Center 40 participants Est. completion 2023-04-01 1 site Stand-alone
    Other conditions: Thymic Epithelial Tumor
    View official trial listing →
  • Withdrawn NCT NCT03881111

    First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

    Not yet reported Merck Sharp & Dohme LLC Est. completion 2022-05-11 20 sites Stand-alone
    Other conditions: Esophageal Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT03891979

    Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

    Not yet reported NYU Langone Health Est. completion 2020-06-01 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Terminated NCT NCT03894540

    Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

    Not yet reported Ipsen 22 participants Est. completion 2020-12-21 1 site Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Terminated NCT NCT03917381

    GEN1046 Safety Trial in Patients With Malignant Solid Tumors

    Not yet reported, Not yet reported Genmab 429 participants Est. completion 2026-08-03 57 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT03921021

    Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

    Not yet reported Weill Medical College of Cornell University 17 participants Est. completion 2023-07-20 3 sites Stand-alone
    Other conditions: Esophagogastric Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT03922204

    A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

    Not yet reported Merus B.V. 72 participants Est. completion 2024-11-07 8 sites Stand-alone
    Other conditions: Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
    View official trial listing →
  • Completed NCT NCT03934814

    Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

    Not yet reported I-Mab Biopharma US Limited 98 participants Est. completion 2023-01-10 21 sites Stand-alone
    Other conditions: Solid Tumor, Lymphoma
    View official trial listing →
  • Terminated NCT NCT03938337

    Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer

    Not yet reported University of Alabama at Birmingham 1 participants Est. completion 2020-04-03 1 site Stand-alone
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT03939975

    Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

    Not yet reported Sun Yat-sen University 50 participants Est. completion 2019-07-31 1 site Stand-alone
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Active, not recruiting NCT NCT03970746

    Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

    Not yet reported, Not yet reported PDC*line Pharma SAS 73 participants Est. completion 2025-12 16 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03978689

    A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

    Not yet reported Cue Biopharma 80 participants Est. completion 2026-01-04 17 sites
    Other conditions: Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
    View official trial listing →
  • Terminated NCT NCT03983668

    CMP-001 for Relapsed and Refractory Lymphoma

    Not yet reported, Not yet reported Umar Farooq 14 participants Est. completion 2025-04-08 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT03996473

    Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

    Not yet reported Bayer 8 participants Est. completion 2023-01-30 6 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Active, not recruiting NCT NCT04009967

    Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

    Not yet reported CHU de Quebec-Universite Laval 30 participants Est. completion 2025-03-30 1 site Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT04027946

    LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported National Cancer Institute (NCI) 6 participants Est. completion 2023-12-22 1 site Stand-alone
    Other conditions: Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
    View official trial listing →
  • Active, not recruiting NCT NCT04032418

    Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

    Not yet reported Roswell Park Cancer Institute 9 participants Est. completion 2026-06-14 1 site Stand-alone
    Other conditions: Lung Non-Small Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04046133

    Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

    Not yet reported Cardiff University 52 participants Est. completion 2026-11-30 11 sites Stand-alone
    Other conditions: Anal Cancer Stage III A, Anal Cancer Stage III B
    View official trial listing →
  • Completed NCT NCT04056026

    A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma

    Not yet reported ProgenaBiome 1 participants Est. completion 2018-12-18 1 site
    Other conditions: Mesothelioma
    View official trial listing →
  • Active, not recruiting NCT NCT04069273

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

    Not yet reported Harry H Yoon 58 participants Est. completion 2027-12-10 2 sites Stand-alone
    Other conditions: Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
    View official trial listing →
  • Terminated NCT NCT04074759

    FPT155 in Patients With Advanced Solid Tumors

    Not yet reported Five Prime Therapeutics, Inc. 80 participants Est. completion 2021-08-10 12 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT04083599

    GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

    Not yet reported, Not yet reported Genmab 350 participants Est. completion 2027-01 76 sites Stand-alone
    Other conditions: Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
    View official trial listing →
  • Status unknown NCT NCT04091932

    Treatment of PD-1 Inhibitor in AIDS-associated PML

    Not yet reported First Affiliated Hospital of Zhejiang University 10 participants Est. completion 2021-12 1 site Stand-alone
    Other conditions: Progressive Multifocal Leukoencephalopathy, AIDS
    View official trial listing →
  • Completed NCT NCT04098068

    Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12 participants Est. completion 2025-02-05 3 sites Stand-alone
    Obstructive sleep apnea Other conditions: High Tumor Mutation Burden, High TMB (Tumor Mutation Burden)
    View official trial listing →
  • Withdrawn NCT NCT04129515

    NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

    Not yet reported, Not yet reported Brown University Est. completion 2026-01 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Melanoma Brain Metastasis
    View official trial listing →
  • Active, not recruiting NCT NCT04130516

    Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

    Not yet reported, Not yet reported Linnaeus Therapeutics, Inc. 200 participants Est. completion 2026-08-15 10 sites
    Other conditions: Solid Tumor, Adult
    View official trial listing →
  • Terminated NCT NCT04135352

    A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

    Not yet reported Merck Sharp & Dohme LLC 35 participants Est. completion 2022-08-24 6 sites Stand-alone
    Other conditions: Neoplasm Metastasis
    View official trial listing →
  • Active, not recruiting NCT NCT04140526

    Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

    Not yet reported, Not yet reported OncoC4, Inc. 733 participants Est. completion 2027-12-31 37 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT04153734

    Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

    Not yet reported Kobe Minimally Invasive Cancer Center 21 participants Est. completion 2023-11-30 Stand-alone
    Other conditions: Locally Advanced Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04165096

    KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

    Not yet reported Merck Sharp & Dohme LLC 128 participants Est. completion 2025-05-28 39 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Terminated NCT NCT04171219

    Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

    Not yet reported M.D. Anderson Cancer Center 31 participants Est. completion 2025-03-11 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT04171622

    Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

    Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2027-08-31 1 site Stand-alone
    Other conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04185883

    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Not yet reported Amgen 610 participants Est. completion 2027-12-05 90 sites Stand-alone
    Other conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
    View official trial listing →
  • Active, not recruiting NCT NCT04194944

    A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    Not yet reported Eli Lilly and Company 261 participants Est. completion 2030-06 196 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT04197219

    Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

    Not yet reported Case Comprehensive Cancer Center Est. completion 2026-12-01 Stand-alone
    Other conditions: Recurrent Endometrial Cancer
    View official trial listing →
  • Withdrawn NCT NCT04201145

    Pembrolizumab + Defactinib In Pleural Mesothelioma

    Not yet reported Raphael Bueno, MD Est. completion 2022-12-31 2 sites Stand-alone
    Other conditions: Malignant Pleural Mesothelioma
    View official trial listing →
  • Active, not recruiting NCT NCT04205227

    ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

    Not yet reported, Not yet reported ENB Therapeutics, Inc 137 participants Est. completion 2026-03-31 5 sites Stand-alone
    Other conditions: Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT04207086

    A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

    Not yet reported Melanoma Institute Australia 21 participants Est. completion 2033-01-01 1 site Stand-alone
    Other conditions: Melanoma Stage III
    View official trial listing →
  • Completed NCT NCT04209686

    Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19 participants Est. completion 2025-11-17 1 site Stand-alone
    Other conditions: Advanced Gastric Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT04211103

    Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions

    Not yet reported Fondazione Policlinico Universitario Agostino Gemelli IRCCS 45 participants Est. completion 2024-09-01 9 sites Stand-alone
    Other conditions: Cervical, Vaginal and Vulval Inflammatory Diseases
    View official trial listing →
  • Withdrawn NCT NCT04220892

    Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

    Not yet reported Jose Carrillo Est. completion 2020-07-08 1 site Stand-alone
    Other conditions: High Grade Glioma
    View official trial listing →
  • Status unknown NCT NCT04224480

    Longitudinal Immune-phenotyping of HCC Following MK-3475

    Not yet reported National Cancer Centre, Singapore 8 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04238988

    Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

    Not yet reported Fondazione Policlinico Universitario Agostino Gemelli IRCCS 45 participants Est. completion 2023-09-01 1 site Stand-alone
    Other conditions: Locally Advanced Cervical Cancer
    View official trial listing →
  • Withdrawn NCT NCT04258683

    A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

    Not yet reported Canadian Myeloma Research Group Est. completion 2022-10-31 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Suspended NCT NCT04266730

    Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

    Not yet reported UNC Lineberger Comprehensive Cancer Center 6 participants Est. completion 2033-06-01 1 site Stand-alone
    Other conditions: Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
    View official trial listing →
  • Status unknown NCT NCT04268368

    Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors

    Università Politecnica delle Marche 200 participants Est. completion 2022-01-01 1 site
    Other conditions: Cancer, Lung Cancer, Renal Cell Carcinoma, Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT04284787

    BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 60 participants Est. completion 2027-01-30 29 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04305795

    An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

    Not yet reported, Not yet reported Rakuten Medical, Inc. 23 participants Est. completion 2027-06 7 sites
    Other conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04306042

    A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

    Guangdong Association of Clinical Trials 1000 participants Est. completion 2022-12 1 site
    Other conditions: Lung Squamous Cell Carcinoma Stage IV
    View official trial listing →
  • Status unknown NCT NCT04355806

    Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

    Shanghai Pulmonary Hospital, Shanghai, China 160 participants Est. completion 2023-05-31 2 sites
    Other conditions: Non Small Cell Lung Cancer, Influenza Vaccine
    View official trial listing →
  • Status unknown NCT NCT04359199

    QUantitative Assessment of Swallowing After Radiation (QUASAR)

    Loren Mell, MD 42 participants Est. completion 2024-12-31 2 sites
    Other conditions: Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT04370509

    Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

    Not yet reported University of California, San Francisco 6 participants Est. completion 2025-02-28 1 site Stand-alone
    Other conditions: Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04389177

    Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 50 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: Esophageal Squamous Cell Carcinoma, Stage III
    View official trial listing →
  • Active, not recruiting NCT NCT04393350

    Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

    Not yet reported Emory University 18 participants Est. completion 2026-12-11 1 site Stand-alone
    Other conditions: Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04417166

    Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 30 participants Est. completion 2026-12 2 sites Stand-alone
    Other conditions: Lymphoma, Extranodal NK-T-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT04430738

    Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

    Not yet reported Seagen, a wholly owned subsidiary of Pfizer 40 participants Est. completion 2026-12-31 27 sites Stand-alone
    Other conditions: Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04443348

    Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

    Not yet reported Laura M. Spring, MD 120 participants Est. completion 2026-12-31 10 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
    View official trial listing →
  • Status unknown NCT NCT04447092

    Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

    Not yet reported Seoul National University Hospital 77 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Pancreatic Cancer, Chemotherapy Effect
    View official trial listing →
  • Active, not recruiting NCT NCT04448886

    Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

    Not yet reported Ana C Garrido-Castro, MD 110 participants Est. completion 2027-06-01 8 sites Stand-alone
    Other conditions: Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04478695

    Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Amgen 1 participants Est. completion 2020-10-23 2 sites Stand-alone
    Other conditions: Relapsed or Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04533451

    Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 101 participants Est. completion 2027-05-31 505 sites Stand-alone
    Other conditions: Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04548752

    Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

    Not yet reported National Cancer Institute (NCI) 88 participants Est. completion 2026-10-01 533 sites Stand-alone
    Other conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04581382

    Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

    Not yet reported Mayo Clinic 18 participants Est. completion 2024-10-06 1 site Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Status unknown NCT NCT04595734

    Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.

    Western Sydney Local Health District 500 participants Est. completion 2025-01-06 3 sites
    Other conditions: Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis
    View official trial listing →
  • Withdrawn NCT NCT04605614

    64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

    Not yet reported City of Hope Medical Center Est. completion 2022-05-16 Stand-alone
    Other conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT04606940

    Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)

    University Health Network, Toronto 18 participants Est. completion 2021-10-12 1 site
    Other conditions: Head and Neck Cancer, Advanced Cancer, Metastatic Cancer, HNSCC, Squamous Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04622007

    Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

    Not yet reported Effector Therapeutics 68 participants Est. completion 2024-12-09 144 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04627012

    Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

    Sun Yat-sen University 600 participants Est. completion 2023-07-01 1 site
    Other conditions: Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
    View official trial listing →
  • Status unknown NCT NCT04631731

    Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

    Not yet reported, Not yet reported Western Sydney Local Health District 200 participants Est. completion 2025-12-10 2 sites
    Other conditions: Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer, Hepatocellular Carcinoma, Endometrial Cancer, Mesothelioma
    View official trial listing →
  • Completed NCT NCT04632459

    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

    Not yet reported Samsung Medical Center 26 participants Est. completion 2025-01-15 2 sites Stand-alone
    Other conditions: Gastric Cancer
    View official trial listing →
  • Terminated NCT NCT04638582

    Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 6 participants Est. completion 2026-04-14 1 site Stand-alone
    Other conditions: Lung Cancer, Nonsmall Cell
    View official trial listing →
  • Status unknown NCT NCT04641728

    Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

    Not yet reported Saitama Medical University International Medical Center 28 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Cervical Cancer
    View official trial listing →
  • Status unknown NCT NCT04660929

    CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

    Not yet reported Carisma Therapeutics Inc 48 participants Est. completion 2024-12-31 7 sites Stand-alone
    Other conditions: HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
    View official trial listing →
  • Terminated NCT NCT04682431

    A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

    Not yet reported Ikena Oncology 127 participants Est. completion 2023-08-31 17 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
    View official trial listing →
  • Status unknown NCT NCT04699071

    Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

    Not yet reported National University Hospital, Singapore 10 participants Est. completion 2025-01 1 site Stand-alone
    Other conditions: Adenocarcinomas, Recurrent Gynecological
    View official trial listing →
  • Withdrawn NCT NCT04703426

    Sargramostim (GM-CSF) + PD-1

    Not yet reported Dana-Farber Cancer Institute Est. completion 2025-06-09 Stand-alone
    Other conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
    View official trial listing →
  • Status unknown NCT NCT04714697

    Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

    Not yet reported Asan Medical Center 201 participants Est. completion 2025-02-28 1 site Stand-alone
    Other conditions: Renal Cell Cancer
    View official trial listing →
  • Completed NCT NCT04716933

    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

    Not yet reported Merck Sharp & Dohme LLC 201 participants Est. completion 2024-08-30 19 sites Stand-alone
    Other conditions: Nonsquamous Non-small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04717375

    Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Sanofi 125 participants Est. completion 2025-07-02 18 sites Stand-alone
    Other conditions: Cancer, Neoplasm
    View official trial listing →
  • Completed NCT NCT04725188

    Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

    Not yet reported Merck Sharp & Dohme LLC 255 participants Est. completion 2024-10-17 95 sites Stand-alone
    Other conditions: Metastatic Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04729348

    Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

    Not yet reported Massachusetts General Hospital 10 participants Est. completion 2024-01-17 2 sites Stand-alone
    Other conditions: Solid Tumor, Solid Tumor, Adult, Leptomeningeal Metastasis
    View official trial listing →
  • Status unknown NCT NCT04764487

    A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

    Not yet reported Weprom 178 participants Est. completion 2025-06-15 13 sites
    Other conditions: Renal Cell Carcinoma Metastatic
    View official trial listing →
  • Terminated NCT NCT04791215

    Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

    Columbia University 10 participants Est. completion 2023-04-12 1 site
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04799054

    A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

    Not yet reported, Not yet reported Ascendis Pharma Oncology Division A/S 188 participants Est. completion 2025-12-02 49 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
    View official trial listing →
  • Terminated NCT NCT04800627

    Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 2 participants Est. completion 2022-11-03 1 site Stand-alone
    Other conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
    View official trial listing →
  • Status unknown NCT NCT04807114

    A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

    Universitaire Ziekenhuizen KU Leuven 70 participants Est. completion 2025-01-31 1 site
    Other conditions: Lung Diseases, Interstitial, NSCLC, Immunotherapy
    View official trial listing →
  • Completed NCT NCT04811027

    Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

    Not yet reported Immutep S.A.S. 171 participants Est. completion 2025-11-05 28 sites Stand-alone
    Other conditions: HNSCC
    View official trial listing →
  • Status unknown NCT NCT04813523

    Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 30 participants Est. completion 2024-03-31 1 site Stand-alone
    Other conditions: Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy, Pembrolizumab
    View official trial listing →
  • Active, not recruiting NCT NCT04825990

    Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

    Not yet reported Gruppo Oncologico del Nord-Ovest 30 participants Est. completion 2026-10-27 1 site Stand-alone
    Other conditions: Nasopharyngeal Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04848337

    Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

    Not yet reported University of Michigan Rogel Cancer Center 45 participants Est. completion 2027-04 5 sites Stand-alone
    Other conditions: Prostate Cancer Metastatic, Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT04854434

    A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

    Not yet reported Karyopharm Therapeutics Inc 13 participants Est. completion 2022-06-24 3 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Status unknown NCT NCT04863079

    Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 82 participants Est. completion 2024-04-30 1 site Stand-alone
    Other conditions: ESCC, Adjuvant Treatment, Lymph Node Positive, Pembrolizumab
    View official trial listing →
  • Active, not recruiting NCT NCT04869137

    Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 26 participants Est. completion 2026-09 1 site Stand-alone
    Other conditions: Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
    View official trial listing →
  • Completed NCT NCT04879849

    A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

    Not yet reported Takeda 34 participants Est. completion 2024-04-30 5 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
    View official trial listing →
  • Not yet recruiting NCT NCT04901741

    Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

    Not yet reported TME Pharma AG 60 participants Est. completion 2029-03 Stand-alone
    Other conditions: Metastatic Pancreatic Cancer
    View official trial listing →
  • Terminated NCT NCT04914897

    A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

    Not yet reported Sanofi 106 participants Est. completion 2024-10-17 35 sites Stand-alone
    Other conditions: Pleural Mesothelioma, Non-small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04920383

    ALPN-202 With PD-1 Inhibition in Advanced Malignancies

    Not yet reported Alpine Immune Sciences, Inc. 29 participants Est. completion 2023-02-28 5 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Lymphoma
    View official trial listing →
  • Terminated NCT NCT04925986

    Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

    Not yet reported Sarah Goldberg 9 participants Est. completion 2023-10-30 1 site Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, PD-L1 Gene Mutation, Advanced Treatment-Naïve PD-L1, Sitravatinib, Pembrolizumab
    View official trial listing →
  • Active, not recruiting NCT NCT04956640

    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

    Not yet reported, Not yet reported Eli Lilly and Company 540 participants Est. completion 2027-04 49 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
    View official trial listing →
  • Status unknown NCT NCT04998474

    FRAME-001 Personalized Vaccine in NSCLC

    Not yet reported Frame Pharmaceuticals B.V. 15 participants Est. completion 2024-07 3 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05033756

    Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

    Not yet reported Institut fuer Frauengesundheit 11 participants Est. completion 2026-02 6 sites Stand-alone
    Other conditions: Malignant Neoplasm of Breast, Breast Cancer
    View official trial listing →
  • Terminated NCT NCT05036681

    A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

    Not yet reported M.D. Anderson Cancer Center 9 participants Est. completion 2025-05-06 1 site Stand-alone
    Other conditions: Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05041153

    Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

    Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2026-12-30 1 site Stand-alone
    Other conditions: Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05082259

    ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

    Not yet reported Institute of Cancer Research, United Kingdom 61 participants Est. completion 2026-12 3 sites Stand-alone
    Other conditions: Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT05091346

    A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

    Not yet reported, Not yet reported Eisai Inc. 89 participants Est. completion 2024-10-15 32 sites Stand-alone
    Other conditions: Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
    View official trial listing →
  • Completed NCT NCT05104567

    A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

    Not yet reported Sanofi 138 participants Est. completion 2024-09-09 29 sites Stand-alone
    Other conditions: Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT05112536

    Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

    Not yet reported G1 Therapeutics, Inc. 24 participants Est. completion 2023-03-13 7 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer, Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05127590

    RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

    Not yet reported, Not yet reported Ribon Therapeutics, Inc. 50 participants Est. completion 2023-12 19 sites Stand-alone
    Other conditions: Advanced Squamous Non-Small Cell Lung Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05131919

    Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

    Not yet reported The Netherlands Cancer Institute 25 participants Est. completion 2031-07 1 site Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Terminated NCT NCT05166577

    Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

    Not yet reported Viracta Therapeutics, Inc. 26 participants Est. completion 2025-01-10 13 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV Related Carcinoma, EBV-Related Sarcoma
    View official trial listing →
  • Terminated NCT NCT05167409

    Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

    Not yet reported University of Colorado, Denver 19 participants Est. completion 2024-10-30 4 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Terminated NCT NCT05179603

    A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

    Not yet reported Sanofi 14 participants Est. completion 2024-09-06 8 sites Stand-alone
    Other conditions: Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05180799

    A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

    Not yet reported, Not yet reported BioAtla, Inc. 320 participants Est. completion 2026-06-30 12 sites Stand-alone
    Other conditions: NSCLC, Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT05195619

    Personalized DC Vaccines in Non Small Cell Lung Cancer

    Not yet reported Centre Hospitalier Universitaire Vaudois 16 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05197322

    NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

    Not yet reported University College, London 88 participants Est. completion 2029-11-01 6 sites
    Other conditions: Adenocarcinoma of the Colon
    View official trial listing →
  • Status unknown NCT NCT05201612

    Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

    Not yet reported Grupo Espanol Multidisciplinario del Cancer Digestivo 40 participants Est. completion 2025-03 15 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Status unknown NCT NCT05222087

    PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study

    Not yet reported Peter MacCallum Cancer Centre, Australia 40 participants Est. completion 2025-04 6 sites Stand-alone
    Other conditions: NSCLC
    View official trial listing →
  • Completed NCT NCT05226728

    Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

    Not yet reported Sun Yat-sen University 33 participants Est. completion 2021-02-01 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT05229614

    Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

    Not yet reported CNAO National Center of Oncological Hadrontherapy 27 participants Est. completion 2026-08 4 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05232851

    A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

    Not yet reported, Not yet reported Mayo Clinic 20 participants Est. completion 2026-09-10 1 site Stand-alone
    Other conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    View official trial listing →
  • Withdrawn NCT NCT05263609

    Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

    Not yet reported University of Oklahoma Est. completion 2027-06 Stand-alone
    Other conditions: Renal Cell Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05286060

    Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

    Not yet reported Yonsei University 56 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05286437

    Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

    Not yet reported National Cancer Centre, Singapore 40 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05296512

    Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

    Not yet reported Elizabeth K. Lee MD 30 participants Est. completion 2028-11-15 3 sites Stand-alone
    Other conditions: Ovarian Clear Cell Carcinoma, Gynecologic Cancer
    View official trial listing →
  • Completed NCT NCT05298423

    Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

    Not yet reported Merck Sharp & Dohme LLC 610 participants Est. completion 2026-06-15 160 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Completed NCT NCT05302011

    Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

    Not yet reported Peking Union Medical College Hospital 28 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Esophageal Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT05311176

    A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

    Not yet reported Imugene Limited 7 participants Est. completion 2024-04-04 7 sites Stand-alone
    Other conditions: Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT05342636

    A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 90 participants Est. completion 2025-12-05 46 sites Stand-alone
    Other conditions: Esophageal Squamous Cell Carcinoma (ESCC)
    View official trial listing →
  • Terminated NCT NCT05346484

    A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

    Not yet reported Imugene Limited 66 participants Est. completion 2026-01-12 12 sites Stand-alone
    Other conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05359445

    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

    Not yet reported Immatics Biotechnologies GmbH 95 participants Est. completion 2029-12 21 sites Stand-alone
    Other conditions: Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05363631

    Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

    Not yet reported, Not yet reported Mohammed Milhem 55 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
    View official trial listing →
  • Active, not recruiting NCT NCT05378425

    A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

    Not yet reported Nectin Therapeutics Ltd 90 participants Est. completion 2026-12 6 sites Stand-alone
    Other conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
    View official trial listing →
  • Terminated NCT NCT05395052

    FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

    Not yet reported Fate Therapeutics 5 participants Est. completion 2023-08-11 5 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
    View official trial listing →
  • Status unknown NCT NCT05429697

    Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

    Not yet reported, Not yet reported SMT bio Co., Ltd. 128 participants Est. completion 2026-06-08 3 sites Stand-alone
    Other conditions: Biliary Tract Cancer
    View official trial listing →
  • Withdrawn NCT NCT05431582

    Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

    Not yet reported M.D. Anderson Cancer Center Est. completion 2022-12-14 Stand-alone
    Other conditions: Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT05432622

    A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

    Bristol-Myers Squibb 95 participants Est. completion 2023-07-11 1 site
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT05446298

    ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

    Not yet reported OncoC4, Inc. 58 participants Est. completion 2026-08-30 21 sites Stand-alone
    Other conditions: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
    View official trial listing →
  • Completed NCT NCT05479812

    Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

    Not yet reported Werewolf Therapeutics, Inc. 156 participants Est. completion 2026-04-22 14 sites Stand-alone
    Other conditions: Metastatic Solid Tumor, Advanced Solid Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT05507541

    TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported Mayo Clinic 10 participants Est. completion 2027-07-30 2 sites Stand-alone
    Other conditions: Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory ALK Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Gray Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT05514444

    Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

    Not yet reported Merck Sharp & Dohme LLC 64 participants Est. completion 2025-09-18 6 sites Stand-alone
    Other conditions: Advanced/Metastatic Solid Tumors, Neoplasms
    View official trial listing →
  • Status unknown NCT NCT05551767

    Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

    Not yet reported City Clinical Oncology Hospital No 1 120 participants Est. completion 2024-12-30 3 sites Stand-alone
    Other conditions: Neck Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05565378

    A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

    Not yet reported GlaxoSmithKline 351 participants Est. completion 2027-12-06 99 sites
    Other conditions: Lung Cancer, Non-Small Cell
    View official trial listing →
  • Completed NCT NCT05600309

    A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

    Not yet reported Merck Sharp & Dohme LLC 94 participants Est. completion 2025-02-21 24 sites Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05609578

    Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

    Not yet reported Mirati Therapeutics Inc. 90 participants Est. completion 2026-12-01 94 sites Stand-alone
    Other conditions: Advanced NSCLC, Metastatic Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT05635344

    A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

    Not yet reported Imperial College London 20 participants Est. completion 2026-08-01 1 site Stand-alone
    Other conditions: Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, Gestational Trophoblastic Tumor, Recurrent
    View official trial listing →
  • Active, not recruiting NCT NCT05653882

    A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

    Not yet reported Asher Biotherapeutics, Inc. 552 participants Est. completion 2027-05 20 sites Stand-alone
    Other conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT05668949

    Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center Est. completion 2025-09-23 Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05689671

    Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

    Not yet reported Nikolaj Frost MD 136 participants Est. completion 2026-10 36 sites
    Other conditions: Non-Small Cell Lung Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT05714371

    Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

    Novartis Pharmaceuticals 618 participants Est. completion 2022-01-27 1 site
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT05721755

    Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

    Not yet reported ECOG-ACRIN Cancer Research Group 290 participants Est. completion 2030-03-31 51 sites Stand-alone
    Other conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    View official trial listing →
  • Status unknown NCT NCT05761132

    Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study

    Not yet reported Leiden University Medical Center 40 participants Est. completion 2025-02-01 Stand-alone
    Other conditions: Vulva Cancer, Vulva Neoplasm, Squamous Cell Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05761951

    Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

    Not yet reported M.D. Anderson Cancer Center 8 participants Est. completion 2029-01-31 1 site Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Status unknown NCT NCT05763992

    Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 145 participants Est. completion 2026-05-15 1 site Stand-alone
    Other conditions: Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting
    View official trial listing →
  • Active, not recruiting NCT NCT05843448

    IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

    Not yet reported University of California, Davis 6 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05853367

    Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

    Not yet reported Merck Sharp & Dohme LLC 95 participants Est. completion 2028-06-24 25 sites Stand-alone
    Other conditions: Metastatic Solid Tumors, Advanced Solid Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT05887492

    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

    Not yet reported, Not yet reported Tango Therapeutics, Inc. 126 participants Est. completion 2026-09 13 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05913388

    GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

    Not yet reported Providence Health & Services 12 participants Est. completion 2030-02 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT05980598

    TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

    Not yet reported Ascendis Pharma A/S 27 participants Est. completion 2025-03-28 65 sites Stand-alone
    Other conditions: Head and Neck Neoplasms
    View official trial listing →
  • Terminated NCT NCT05996445

    A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

    Not yet reported Xencor, Inc. 7 participants Est. completion 2024-05-21 3 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Terminated NCT NCT05998447

    GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

    Not yet reported Genome & Company 10 participants Est. completion 2024-11-26 6 sites Stand-alone
    Other conditions: Biliary Tract Cancer
    View official trial listing →
  • Completed NCT NCT06011330

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

    Hunan Cancer Hospital 70 participants Est. completion 2023-02-10 1 site
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06027268

    Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

    Not yet reported Wake Forest University Health Sciences 36 participants Est. completion 2027-08 1 site Stand-alone
    Other conditions: Metastatic Triple-Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT06035744

    CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

    Not yet reported Cullinan Therapeutics Inc. 23 participants Est. completion 2026-06-16 5 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Terminated NCT NCT06046482

    Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2024-08-26 1 site Stand-alone
    Other conditions: Head Neck, Squamous Cell Carcinoma of Head and Neck
    View official trial listing →
  • Active, not recruiting NCT NCT06082167

    Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not yet reported, Not yet reported Exelixis 600 participants Est. completion 2029-03 168 sites Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06128863

    Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

    Not yet reported Maria Sklodowska-Curie National Research Institute of Oncology 40 participants Est. completion 2027-04-30 1 site
    Other conditions: Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue, Radiation Therapy
    View official trial listing →
  • Not yet recruiting NCT NCT06142617

    A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

    Not yet reported Peking Union Medical College Hospital 37 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
    View official trial listing →
  • Completed NCT NCT06153238

    A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

    Not yet reported Sandoz 322 participants Est. completion 2026-05-05 61 sites
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT06157541

    T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

    Not yet reported, Not yet reported Queensland Institute of Medical Research 58 participants Est. completion 2028-01 4 sites Stand-alone
    Other conditions: Glioblastoma Multiforme, Astrocytoma, Grade IV
    View official trial listing →
  • Active, not recruiting NCT NCT06164275

    Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

    Not yet reported Northwestern University 30 participants Est. completion 2031-12-31 4 sites Stand-alone
    Other conditions: Classic Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT06188208

    A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

    Not yet reported Vividion Therapeutics, Inc. 132 participants Est. completion 2026-02-20 20 sites Stand-alone
    Other conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
    View official trial listing →
  • Withdrawn NCT NCT06190249

    Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

    Not yet reported James Isaacs, MD Est. completion 2028-07 Stand-alone
    Other conditions: Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma
    View official trial listing →
  • Enrolling by invitation NCT NCT06204614

    Drug Screening Using IMD in Bladder Cancer

    Not yet reported Brigham and Women's Hospital 18 participants Est. completion 2028-08-01 1 site Stand-alone
    Other conditions: Muscle Invasive Bladder Urothelial Carcinoma
    View official trial listing →
  • Status unknown NCT NCT06205732

    A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

    Qianfoshan Hospital 100 participants Est. completion 2024-12 1 site
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Active, not recruiting NCT NCT06212752

    A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

    Not yet reported Merck Sharp & Dohme LLC 39 participants Est. completion 2028-05-22 18 sites Stand-alone
    Other conditions: Metastatic Non-small Cell Lung Cancer
    View official trial listing →
  • Suspended NCT NCT06219174

    Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 45 participants Est. completion 2029-08 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Lung Cancer
    View official trial listing →
  • Completed NCT NCT06236425

    TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 7 participants Est. completion 2025-04-09 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06242834

    Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

    Not yet reported Northwestern University 11 participants Est. completion 2028-11-24 2 sites Stand-alone
    Other conditions: B-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06246110

    A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

    Not yet reported Eikon Therapeutics 70 participants Est. completion 2027-12 38 sites Stand-alone
    Other conditions: NSCLC
    View official trial listing →
  • Active, not recruiting NCT NCT06295731

    INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

    Not yet reported, Not yet reported Inhibrx Biosciences, Inc 410 participants Est. completion 2029-05 87 sites Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
    View official trial listing →
  • Terminated NCT NCT06295809

    A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 46 participants Est. completion 2026-03-05 106 sites Stand-alone
    Other conditions: Carcinoma, Squamous Cell, Skin Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT06348199

    A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

    Not yet reported Samsung Bioepis Co., Ltd. 555 participants Est. completion 2026-09 93 sites
    Other conditions: Non-small Cell Lung Cancer Stage IV
    View official trial listing →
  • Active, not recruiting NCT NCT06430866

    Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

    Not yet reported Amgen 163 participants Est. completion 2026-12-14 128 sites
    Other conditions: Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Active, not recruiting NCT NCT06448312

    A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet reported Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 406 participants Est. completion 2026-11 64 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06483334

    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 38 participants Est. completion 2028-03-31 25 sites Stand-alone
    Other conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT06513884

    A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

    Not yet reported, Not yet reported Hookipa Biotech GmbH Est. completion 2032-04 Stand-alone
    Other conditions: Oropharyngeal Squamous Cell Carcinoma Recurrent
    View official trial listing →
  • Status unknown NCT NCT06550453

    Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer

    Not yet reported yangjianjun 20 participants Est. completion 2026-01-15 1 site Stand-alone
    Other conditions: Locally Advanced Colorectal Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06567600

    Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

    Not yet reported Third Affiliated Hospital, Sun Yat-Sen University 43 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
    View official trial listing →
  • Active, not recruiting NCT NCT06584435

    A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer

    Not yet reported Tianjin Medical University Second Hospital 100 participants Est. completion 2027-11-01 1 site Stand-alone
    Other conditions: High-risk Renal Cell Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT06694350

    Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

    Not yet reported Zhejiang Provincial People's Hospital 54 participants Est. completion 2027-12 Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT06704724

    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

    Not yet reported Pfizer 30 participants Est. completion 2026-05-12 13 sites Stand-alone
    Other conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Terminated NCT NCT06716853

    A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

    Not yet reported, Not yet reported Genenta Science 10 participants Est. completion 2026-01-23 1 site Stand-alone
    Other conditions: Clear Cell RCC
    View official trial listing →
  • Active, not recruiting NCT NCT06806852

    A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

    Not yet reported Boehringer Ingelheim 91 participants Est. completion 2027-08-31 51 sites Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT06823323

    The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 150 participants Est. completion 2026-06-01 Stand-alone
    Other conditions: Metastatic Colorectal Cancer (CRC)
    View official trial listing →
  • Not yet recruiting NCT NCT06888037

    Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

    Not yet reported Ruijin Hospital 55 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy, Fruquintinib, PD-1
    View official trial listing →
  • Not yet recruiting NCT NCT06916416

    Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

    Not yet reported University of Cologne 50 participants Est. completion 2028-06 Stand-alone
    Other conditions: Classical Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT06939036

    Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

    Not yet reported, Not yet reported Ariceum Therapeutics GmbH 2 participants Est. completion 2025-12-31 7 sites Stand-alone
    Other conditions: Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07010393

    Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

    Not yet reported Fujian Medical University 335 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Thyroid Neoplasms
    View official trial listing →
  • Not yet recruiting NCT NCT07020052

    Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 33 participants Est. completion 2030-07-30 1 site
    Other conditions: Maintenance Treatment of Diffuse Midline Gliomas in Children
    View official trial listing →
  • Not yet recruiting NCT NCT07035860

    Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer

    Ji Yongling 34 participants Est. completion 2028-06-15 1 site
    Other conditions: Carbon Ion Radiotheray
    View official trial listing →
  • Not yet recruiting NCT NCT07054242

    A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

    Not yet reported Yantai Yuhuangding Hospital 52 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07067450

    Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

    Not yet reported Sichuan University 98 participants Est. completion 2026-12-31 Stand-alone
    Other conditions: Esophageal Squamous Cell Carcinoma (ESCC)
    View official trial listing →
  • Withdrawn NCT NCT07073183

    Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

    Not yet reported CureVac Est. completion 2029-12-31 13 sites Stand-alone
    Other conditions: Squamous NSCLC
    View official trial listing →
  • Not yet recruiting NCT NCT07300475

    Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

    Not yet reported Washington University School of Medicine 30 participants Est. completion 2035-06-30 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07360132

    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

    Not yet reported Shanghai Huaota Biopharmaceutical Co., Ltd. 480 participants Est. completion 2028-08-10 1 site
    Other conditions: Squamous Non-small Cell Lung Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07368985

    Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

    Not yet reported Prof. Dr. Remi A. Nout 87 participants Est. completion 2029-10 1 site Stand-alone
    Other conditions: Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
    View official trial listing →
  • Active, not recruiting NCT NCT07428252

    Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

    Not yet reported Institute of Oncology Ljubljana 150 participants Est. completion 2026-03-31 1 site
    Other conditions: Metastatic Malignant Melanoma
    View official trial listing →
  • Not yet recruiting NCT NCT07509099

    Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

    Not yet reported Ji Dongmei 316 participants Est. completion 2031-09-30 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma of Head and Neck
    View official trial listing →
  • Not yet recruiting NCT NCT07591597

    A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

    Not yet reported, Not yet reported National Cancer Center Hospital East 68 participants Est. completion 2029-05 Stand-alone
    Obstructive sleep apnea Other conditions: Metastatic Colorectal Neoplasms
    View official trial listing →
  • Not yet recruiting NCT NCT07661251

    ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)

    Laura Longshaw 60 participants Est. completion 2028-04
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07680088

    Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer

    Not yet reported University of Texas Southwestern Medical Center 17 participants Est. completion 2030-09-30 Stand-alone
    Other conditions: Anal Squamous Cell Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07720180

    Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

    Not yet reported Medical University of South Carolina 20 participants Est. completion 2032-12-01 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07772882

    Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

    Not yet reported Rebecca Arend 24 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers, Peritoneal Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07788664

    Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)

    Not yet reported Vall d'Hebron Institute of Oncology 50 participants Est. completion 2030-06-01 3 sites
    Other conditions: Advanced Gastric Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07791615

    A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20 participants Est. completion 2029-06 Stand-alone
    Other conditions: Lymphoma, NK T-Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07822373

    A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer

    Not yet reported University of Utah 25 participants Est. completion 2035-11 1 site Stand-alone
    Other conditions: Muscle-invasive Bladder Urothelial Carcinoma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pembrolizumab, KEYTRUDA QLEX, KEYTRUDA

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.